Skip to content

Time From PCI to Cancer Surgery and Cardiovascular and Oncologic Outcomes

Association Between Time From PCI to Cancer Surgery and Cardiovascular and Oncologic Outcomes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06357000
Enrollment
3621
Registered
2024-04-10
Start date
2008-01-01
Completion date
2018-12-31
Last updated
2024-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Coronary Artery Disease

Keywords

Time, Percutaneous coronary intervention, Cancer surgery

Brief summary

To evaluate the association between time from PCI to cancer surgery and cardiovascular and oncologic outcomes in early-stage cancer patients, A retrospective, population-based cohort study was conducted using data from the Korean National Health Insurance Service (K-NHIS) database.

Detailed description

Early-stage-cancer patients with a history of PCI who underwent cancer surgery (N = 3621) were included. The patients were divided into two groups based on the time between the dates of PCI and cancer surgery (<12 months and ≥12 months). Patients were stratified into early-surgery and late-surgery, defined as patients who underwent surgery ≥1 and <1 month after cancer diagnosis. Outcomes included bleeding, spontaneous myocardial infarction (MI), repeat revascularization, cancer recurrence, and death.

Interventions

None listed

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* men and women aged ≥18 years who were diagnosed with cancer and underwent cancer surgery within 1 year following diagnosis. * patients who underwent PCI (procedure code: M6551-M6572, O1640-O1649, OA640-OA649) prior to the cancer surgery

Exclusion criteria

* participants who received neoadjuvant or adjuvant treatment for cancer

Design outcomes

Primary

MeasureTime frameDescription
Occurence of Bleedingup to 5 yearsBleeding requiring transfusion was defined by the transfusion codes (X2021, X2022, X2031, X2032, X2091, X2092, X2111, X2112, X2131, X2132).

Secondary

MeasureTime frameDescription
Occurence of Spontaneous myocardial infarctionup to 5 yearsSpontaneous myocardial infarction (MI) was defined as hospitalization for MI (ICD-10 codes I21 and I22)
Occurence of Repeat revascularizationup to 5 yearsRepeat revascularization was defined as the presence of a procedure code after cancer surgery.
Occurence of Cancer recurrenceup to 5 yearsCancer recurrence was defined as the presence of chemotherapy and/or radiation therapy that began more than 6 months after surgery completion.
Occurence of All cause deathup to 5 yearsVital status was obtained from death certification collected by Statistics Korea at the Ministry of Strategy and Finance of South Korea.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026